| Foa, Roberto |
GIMEMA, NCT01361438: De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients |
|
|
| Active, not recruiting | 2 | 60 | Europe | Total therapy approach | Gruppo Italiano Malattie EMatologiche dell'Adulto | ALL Ph Positive | 10/14 | 12/20 | | |
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 156 | Europe | Ibrutinib, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocyte Leukemia, Adult Patients | 04/18 | 04/24 | | |
| Completed | 2 | 77 | Europe | Venetoclax, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia | 09/21 | 05/23 | | |
| Active, not recruiting | 2 | 149 | Europe | Chemotherapy + Blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor | 02/24 | 02/24 | | |
NCT02185781: Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) |
|
|
| Completed | 1 | 6 | Europe | Autologous NK cells infusions | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD) | 11/21 | 11/21 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
| Mauro, Francesca Romana |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche | Chronic Lymphoid Leukemia | 09/27 | 09/27 | | |
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 156 | Europe | Ibrutinib, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocyte Leukemia, Adult Patients | 04/18 | 04/24 | | |
| Completed | 2 | 77 | Europe | Venetoclax, Rituximab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia | 09/21 | 05/23 | | |
NCT02388048 / 2015-000684-13: Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 19 | Europe | Ibrutinib + ofatumumab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Leukemia, Lymphoblastic, Chronic | 04/24 | 04/24 | | |
VIS, NCT05478512 / 2022-002579-12: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL |
|
|
| Recruiting | 2 | 78 | Europe | VenObi+Ven or VenObi+VenZan | Gruppo Italiano Malattie EMatologiche dell'Adulto, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus | High Risk CLL, Chronic Lymphocytic Leukemia | 05/26 | 07/27 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. |
|
|
| Recruiting | N/A | 954 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi | Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19 | 09/24 | 09/24 | | |
| Iori, Anna Paola |
| Active, not recruiting | 2 | 120 | Europe | Pentaglobin | Gruppo Italiano Trapianto di Midollo Osseo | Septic Shock | 05/24 | 05/25 | | |
| Petrucci, Maria Teresa |
NCT05393024: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy |
|
|
| Completed | N/A | 78 | Europe | Belantamab mafodotin | Fondazione EMN Italy Onlus | Multiple Myeloma | 08/24 | 08/24 | | |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
| Torelli, Giovanni |
NCT02185781: Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) |
|
|
| Completed | 1 | 6 | Europe | Autologous NK cells infusions | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD) | 11/21 | 11/21 | | |
| Grammatico, Sara |
CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 520 | Europe | Quality of life questionnaires | Gruppo Italiano Malattie EMatologiche dell'Adulto | Multiple Myeloma | 12/24 | 12/24 | | |
| Chistolini, Antonio |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients |
|
|
| Recruiting | N/A | 200 | Europe, Canada, US, RoW | | Octapharma | Haemophilia a | 06/30 | 06/30 | | |
| Gentile, Giuseppe |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
| Micozzi, Alessandra |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
| Micozzi, Giuseppe |
| No trials found |
